Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

VANTRELA ER

HYDROCODONE BITARTRATE

Standard Dose
45MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: N/A Marketing status: Discontinued
Summary

Approval overview VANTRELA ER is listed in Drugs@FDA under application 207975 (NDA).

Review priority: N/A Marketing status: Discontinued Active ingredient HYDROCODONE BITARTRATE Form and strength TABLET, EXTENDED RELEASE;ORAL - 45MG Sponsor TEVA BRANDED PHARM Submission history Latest submission status date: 2017-05-26 00:00:00.

Structured Monograph

Clinical summary

Approval overview VANTRELA ER is listed in Drugs@FDA under application 207975 (NDA). Review priority: N/A Marketing status: Discontinued Active ingredient HYDROCODONE BITARTRATE Form and strength TABLET, EXTENDED RELEASE;ORAL - 45MG Sponsor TEVA BRANDED PHARM Submission history Latest submission status date: 2017-05-26 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: N/A

Interaction Notes

  • No interaction notes stored yet.
VANTRELA ER (HYDROCODONE BITARTRATE) | Drug Monograph | MedicHelpline